ClinicalTrials.gg
Active, not recruitingNCT04176172HTOUpdated Sep 4, 2026

Optimizing Tobacco Use Treatment for PLWHA

A Phase 3 interventional study of Varenicline and Nicotine patch in HIV/AIDS and Nicotine Dependence, sponsored by Abramson Cancer Center at Penn Medicine. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Abramson Cancer Center at Penn Medicine · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States — 112 open to participants now, 154 under way, 9 of them phase 3. Acquired Immunodeficiency Syndrome · United States.

Planned enrollment
201st of 1,291
340 · median 60
Started
2020
with 53 others
Phase 3
138 of 1,671
3 open now
Primary completion
2026-11
later than 27 of 150 live
Registered
1,380th of 1,671
by date

Among the 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States, this one is the 201st largest by planned enrollment of the 1,291 interventional ones that give a count, is one of 54 that started in 2020, is one of 138 in phase 3, reaches primary completion later than 27 of the 150 other live ones, and was the 1,380th registered.

Acquired Immunodeficiency Syndrome

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

112 of the 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,671 studies in Acquired Immunodeficiency Syndrome with a site in United States, or all of them as a file.
02

Study summary

The advent of anti-retroviral therapy (ART) for people living with HIV/AIDS (PLWHA) substantially improved life expectancy but has also led to the critical need to address modifiable risk factors associated with cancer and cardiovascular disease, such as tobacco smoking. HIV-infected smokers lose more life-years due to tobacco use than they do to their HIV infection.

There have been relatively few studies of tobacco use treatments for PLWHA and systematic reviews show that there are insufficient data to conclude that tobacco dependence interventions that are efficacious in the general population are efficacious for PLWHA. Further, many studies in this area have lacked randomization and a control group, infrequently used an intent-to-treat (ITT) approach and biological verification of tobacco abstinence, and lacked post-treatment follow-up.10 What investigators do know thus far is that behavioral interventions and the nicotine patch yield moderate effects on cessation; and 2 recent placebo-controlled trials - one in France and one by this lab - found that varenicline is safe and effective for treating tobacco use among PLWHA, but yield quit rates that are substantially lower than those reported in the general population. Thus, there is a critical need to rigorously test novel ways to optimize tobacco cessation treatment for smokers with HIV.

Read the detailed description

Smoking among PLWHA is a critical public health issue, with the rate of smoking 2-3 times greater than it is in the general population and the health risks of smoking outweighing those associated with the virus itself. Unfortunately, remarkably few studies have evaluated smoking cessation interventions for PLWHA and the available literature indicates that both behavioral and pharmacological smoking cessation interventions yield modest effect sizes and quit rates that are considerably lower than in the general population. A sizable literature, including studies by our research team, indicates that using the nicotine metabolite ratio (NMR) to personalize the selection of medications for tobacco use and the MAPS intervention to augment adherence to these medications can optimize treatments for tobacco use among PLWHA. The NCI recognized the potential for clinicians to use the NMR to individualize cessation treatment in order to improve effectiveness (https://www.cancer.gov/about-nci/budget/plan/public-health) and the Centers for Disease Control and Prevention (CDC) has endorsed MAPS as an evidence-based approach to increasing medication adherence among PLWHA. As such, this trial will test these intervention optimization strategies to determine if individually or together they can represent an effective approach to treating tobacco use in this under-served population of smokers. As a major advance for this area of work, the investigators will use rigorous methodology to evaluate these optimization strategies (i.e., a randomized design, biological verification, an ITT approach, and 6-month outcome assessments) and, overall, our approach is consistent with the multiphase optimization strategy (MOST) framework, which has been used to identify intervention components that maximize cessation outcomes. This trial will also assess theoretically derived and empirically based mechanisms through which these optimization strategies affect cessation and explore sub-groups who are more or less responsive to these strategies. In the end, this trial, which is consistent with the Office of AIDS Research trans-NIH Strategic Plan for HIV and HIV-Related Research (https://www.oar.nih.gov/hiv-policy-and-research/research-priorities), will determine if getting the right medication to the right person and making sure they adequately use the medication optimizes tobacco cessation treatments among PLWHA as a critical way to improve health outcomes for this population.

03

Conditions studied

  • HIV/AIDS
  • Nicotine Dependence

Keywords

  • Smoking Cessation
  • Nicotine Dependence
  • HIV/AIDS
  • Varenicline
  • Nicotine Patch
  • Cigarette Smoking
  • Managed Problem Solving
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • >18 years, smoke daily for the past 30 days
  • Confirmed + (exhibit viral load of \<1000 copies/mL)
  • Residing in the geographic area close to one of the sites for at least 7 months
  • Able to use varenicline/TN patch safely

Key Exclusion Criteria:

  • Current untreated and unstable diagnosis of substance abuse/dependence
  • Current diagnosis of unstable and untreated major depression, psychosis or bipolar disorder
  • Suicide risk as measured by the C-SSRS
  • Current use or discontinuation within last 14 days of quit smoking medications
  • Cancer, heart disease, stroke or MI within the past 6 months requires study physician approval
  • Uncontrolled hypertension
  • History of epilepsy or seizure disorder requires study physician approval
  • Women who are pregnant, planning a pregnancy, or lactating
  • Use of e-cigarettes, chewing tobacco, snuff or snus
  • Generalized eczema or psoriasis
  • A reaction or sensitivity to a nicotine patch or any other transdermal medication requires study physician approval
  • Currently participating in a smoking cessation program
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
340 participants (estimated)

Study arms

  • Active comparator
    Varenicline & Standard Cessation Counseling

    varenicline plus standard behavioral smoking cessation treatment

    Drug: Varenicline · Behavioral: Standard treatment

  • Experimental
    NMR-Tailored Medication & Standard Cessation Counseling + MAPS

    varenicline or nicotine patch plus standard behavioral smoking cessation treatment with Managed Problem Solving adherence intervention

    Drug: Varenicline · Drug: Nicotine patch · Behavioral: Standard treatment + Managed Problem Solving (MAPS) adherence intervention

Interventions

  • Participants will receive open-label varenicline for 12 weeks.

    Also known as: Chantix or Apo-Varenicline

  • Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)

    Also known as: NicoDerm

  • BehavioralStandard treatment

    Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks.

    Also known as: Standard Therapy

  • BehavioralStandard treatment + Managed Problem Solving (MAPS) adherence intervention

    Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Managed Problem Solving (MAPS) is a therapeutic process that involves the systematic delineation of a participant's medication adherence problems and construction of a series of individualized solutions that therapists and participants explore together. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks. The first session will directly address potential medication adherence barriers, and therapist and participant will collaboratively brainstorm ways to overcome these barriers.

    Also known as: Standard treatment + MAPS

06

What researchers measure

Primary outcomes

  1. Point-prevalence abstinence

    Participants will be considered abstinent if they report abstinence, not even a puff of a cigarette, for \>7 days prior to week 26 (24 weeks post target quit date) and have an expired carbon monoxide reading of ≤8 parts per million at week 26.

    Time frame: 26 weeks (24 weeks post target quit date)

Secondary outcomes

  1. Six-month quit rate

    The number of days in a six-month period of self-reported smoking

    Time frame: 6 months

  2. Prolonged abstinence

    \<7 consecutive days of self-reported smoking after a 2-week grace period

    Time frame: 26 weeks (24 weeks post target quit date)

  3. Continuous abstinence

    No smoking between target quit date (week 2) and week 26

    Time frame: 26 weeks (24 weeks post target quit date)

  4. Time to 7-day relapse

    Time to relapse as defined by 7 or more consecutive days of self-reported smoking (no grace period)

    Time frame: 26 weeks (24 weeks post target quit date)

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Nov 2026, 81 months after the start.

Of 31 non-industry phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 51. This study's planned 81 months is above that.

Counting every sponsor, half of 66 studies reached it within 26 months; a quarter within 19 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2019
First posted
Nov 25, 2019
StartActual
Feb 17, 2020
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04176172
Responsible party
Robert Schnoll, PhD (Professor and Director, Center for Interdisciplinary Research on Nicotine, University of Pennsylvania) — Principal investigator
First posted
Nov 25, 2019
Start date
Feb 17, 2020
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Sep 4, 2026

Study contacts

Robert Schnoll, PhD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nicotine Patch

Start the discussion